Efficacy Profile of T115 Combinations in Treatment of Breast Cancer

Microtubules are cytoskeleton elements in the cell that are important in a number of cellular processes, including mitosis. Their critical role in cell division, the formation of the mitotic spindle, makes them a suitable target of chemotherapeutic drugs. Arora et al. (2009) previously described discovery and development of a novel tubulin binding agent, T115, which inhibits polymerization of microtubules and is effective as a single agent against breast cancer cells both in cell culture and animal models. The novel chemistry, low toxicity, and broad efficacy of this drug warrant a study to test T115 in combination therapy for the treatment of breast cancer. Combination therapy is mostly used in treating cancer as its’ therapeutic efficacy is greater than monotherapy treatment. Hence, the major goal of this project is to establish an efficacy profile of T115 in combination with breast cancer drugs: Doxorubicin and Methotrexate.